ArticleCancer immunology, immunotherapy : CII2010
Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy.
Article in Cancer immunology, immunotherapy : CII, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- The role of CXCR3 and its ligands in cancer.Frontiers in oncology · 2022Review
- Review
- Article
- Enhancer of zeste homolog 2 enhances the migration and chemotaxis of dental mesenchymal stem cells.The Journal of international medical research · 2020Article
- Identification of Key Genes in Thyroid Cancer Microenvironment.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer.Nature communications · 2019Article
- Hub Genes and Key Pathway Identification in Colorectal Cancer Based on Bioinformatic Analysis.BioMed research international · 2019Article
- Down-regulation of CXCL11 inhibits colorectal cancer cell growth and epithelial-mesenchymal transition.OncoTargets and therapy · 2018Article
- Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player?Frontiers in endocrinology · 2018Review
- Development of Fangjiomics for Systems Elucidation of Synergistic Mechanism Underlying Combination Therapy.Computational and structural biotechnology journal · 2018Review
- Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer.Oncotarget · 2017Article
- Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas.Oncotarget · 2017Article
- Chemokine-Derived Peptides: Novel Antimicrobial and Antineoplasic Agents.International journal of molecular sciences · 2015Review
- Role of Chemokines in Non-Small Cell Lung Cancer: Angiogenesis and Inflammation.Journal of Cancer · 2015Review
- Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-λ and elevated secretion of Cxcl10.EMBO molecular medicine · 2013Article
- A novel recombinant protein of IP10-EGFRvIIIscFv and CD8(+) cytotoxic T lymphocytes synergistically inhibits the growth of implanted glioma in mice.Cancer immunology, immunotherapy : CII · 2013Article
- Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity.Toxicological sciences : an official journal of the Society of Toxicology · 2011Article
- CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications.Cytokine & growth factor reviews · 2011Review
- Direct gene transfer with IP-10 mutant ameliorates mouse CVB3-induced myocarditis by blunting Th1 immune responses.PloS one · 2011Article
- CXCR3 ligands: redundant, collaborative and antagonistic functions.Immunology and cell biology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complexity of tumor biology necessitates a multimodality approach that targets different aspects of tumor environment in order to generate the greatest benefit. IFN-inducible T cell alpha chemoattractant (ITAC)/CXCL11 and IFN-inducible protein 10 (IP10)/CXCL10 could exert antitumor effects with functional specificity and thus emerge as attractive candidates for combinatorial strategy. Disappointedly, a synergistic antitumor effect could not be observed when CXCL10 and CXCL11 were pooled together. In this regard, we seek to improve antitumor efficacy by integrating their individual functional moieties into a chemokine chimeric molecule, designated ITIP, which was engineered by substituting the N-terminal and N-loop region of CXCL10 with those of CXCL11. The functional properties of ITIP were determined by chemotaxis and angiogenesis assays. The antitumor efficacy was tested in murine CT26 colon carcinoma, 4T1 mammary carcinoma and 3LL lung carcinoma. Here we showed that ITIP not only exhibited respective functional superiority but strikingly promoted regression of established tumors and remarkably prolonged survival of mice compared with its parent chemokines, either alone or in combination. The chemokine chimera induced an augmented anti-tumor immunity and a marked decrease in tumor vasculature. Antibody neutralization studies indicated that CXCL10 and CXCL11 moieties of ITIP were responsible for anti-angiogenesis and chemotaxis in antitumor response, respectively. These results indicated that integrating individual functional moieties of CXCL10 and CXCL11 into a chimeric chemokine could lead to a synergistic antitumor effect. Thus, this integration strategy holds promise for chemokine-based multiple targeted therapy of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.